Nautilus Biotechnology, Inc. (NAUT)

Nautilus Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	31	28.9	25.95	21.15	3.31
Research & Development	50.48	47.25	37.67	29.35	12.43
Operating Expenses	81.48	76.15	63.62	50.5	15.74
Operating Income	-81.48	-76.15	-63.62	-50.5	-15.74
Interest & Investment Income	10.78	12.55	5.82	0.33	-
Other Non Operating Income (Expenses)	-2.89	-2.73	-1.01	0.17	0.14
EBT Excluding Unusual Items	-73.58	-66.33	-58.81	-50	-15.61
Gain (Loss) on Sale of Investments	2.8	2.66	0.89	-0.18	-
Gain (Loss) on Sale of Assets	-	-	-	-0.14	-0.01
Pretax Income	-70.78	-63.68	-57.92	-50.32	-15.62
Net Income	-70.78	-63.68	-57.92	-50.32	-15.62
Net Income to Common	-70.78	-63.68	-57.92	-50.32	-15.62
Shares Outstanding (Basic)	125	125	125	84	29
Shares Outstanding (Diluted)	125	125	125	84	29
Shares Change (YoY)	0.41%	0.27%	47.51%	190.36%	379.48%
EPS (Basic)	-0.56	-0.51	-0.46	-0.60	-0.54
EPS (Diluted)	-0.56	-0.51	-0.46	-0.60	-0.54
Free Cash Flow	-62.03	-54.15	-48.13	-41.51	-14.92
Free Cash Flow Per Share	-0.49	-0.43	-0.39	-0.49	-0.51
EBITDA	-79.5	-74.3	-62.4	-49.48	-15.03
D&A For EBITDA	1.98	1.85	1.22	1.02	0.71
EBIT	-81.48	-76.15	-63.62	-50.5	-15.74

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q